Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (449)	7/24/2009 9:15:42 AM
From: kenhott	Read Replies (1) \| Respond to of 566

I didn't listen to the conference call yet. But I will try to when I get a little time. A friend who did tells me that the data was in house 48 hours ago and more than the usual suspects had the negative results prior to the CC. So we had the tell tale trading ahead of last night (incl. INCY, even companies like ARRY). I was thinking it must be a safety issue but who knew that it was an efficacy issue. I read the PR, my position is that now the company has to show me. My guess is that they will get it partnered, the issue is the terms and the partner. If they get $25m and 20%, what would the market think? I don't know. I still have to think that thru. But it is not the same potential as before.

To: mopgcw who wrote (449)	10/30/2010 1:28:23 AM
From: tuck	Read Replies (1) \| Respond to of 566

This Taski3 trial analysis notes unusually high placebo response, and suggests the trial was poorly designed in enrolling folks with confounding baseline characteristics: >>Arthritis Rheum. 2010 Oct 27. [Epub ahead of print] An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, Dicarlo J, White ML, O-Brien M, Grossbard EB, Magilavy DB. Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA. Abstract OBJECTIVE.: To assess the efficacy and safety of R788 (Fostamatinib disodium), an inhibitor of Spleen tyrosine kinase (Syk), in patients with active RA who failed biologic therapies. METHODS.: A total of 229 patients with active RA who had currently or previously failed a biologic therapy were enrolled in a 3-month double-blind, placebo-controlled trial of R788. The primary endpoint was the ACR 20 response at Month 3. Secondary endpoints included changes in inflammation and damage assessed by MRI, and changes in DAS. RESULTS.: The ACR 20 response in the R788 100mg BID group was 38% versus 37% in the placebo group at month 3. No significant differences were achieved in the ACR 20/50/70 levels at 3 months. There were differences between the groups in secondary endpoints from Baseline to month 3 in CRP and synovitis scores on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis scores by MRI between R788 group versus placebo which may have affected the outcomes. A high placebo response rate was seen in this trial and exploratory analysis suggests this may in part have been driven by patients who entered the trial with an elevated ESR, but normal CRP. CONCLUSIONS.: No differences in the primary endpoint were seen between the R788 and placebo groups. Differences between the R788 and placebo groups were observed in secondary endpoints, particularly in those patients who entered with an elevated CRP. (ClinicalTrials.Gov Number: NCT00665926).<< However, might one expect elevated ESR in this patient population? Just asking, I don't know the answer. Cheers, Tuck